Drugs / GTE001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06491225 | Jul → Aug 2024 | lung adenocarcinoma | Grit Biotechnology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTE-001 | “GTE-001 injection to treat Advanced lung adenocarcinoma” NCT06491225 ↗ |
| Modality | Cell therapy | “Autologous Tumor-Infiltrating Lymphocyte” NCT06491225 ↗ |